Major review finds vaping likely causes lung and oral cancer
“Researchers have concluded that nicotine vapes are likely to cause lung and oral cancers, based on evidence ranging from human biomarkers to animal and laboratory studies. The findings challenge the idea that vaping is a harmless alternative to smoking and suggest health risks may be emerging much sooner than many expected.”
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
“The company has initiated two Phase III clinical trials within the DAREON® program: DAREON®-Lung-1 in small cell lung cancer (SCLC) and DAREON®-NEC-1 in extrapulmonary neuroendocrine carcinoma (epNEC). In parallel, the Phase III Beamion LUNG-3 trial has been initiated in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC).”
Performance of smoking duration–based lung cancer screening eligibility criteria: a comparative modeling study
“Conclusion: Duration-based screening may be as efficient as current US guidelines. Given their potential to reduce disparities in eligibility shown in recent studies and simpler implementation, duration-based criteria warrant consideration.”
Marked under-diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) in small cell lung cancer: An analysis of real-world claims data
“The presentation highlights the clinical implications of missed LEMS diagnoses, including avoidable morbidity despite available therapies, and emphasizes the need for greater oncology awareness, timely referral, and targeted efforts to improve recognition of this paraneoplastic disorder.”
Scientists found a lung cancer clue in the fine particles people breathe during haze season
“Smoking has long been the main suspect in lung cancer, so declining smoking rates should push cases down. In northern Thailand, however, one form of the disease has continued to climb, and it appears most often in people who never smoked.”
Maintenance Pemetrexed May Not Improve Survival With Pembrolizumab in Advanced Nonsquamous NSCLC
“In a propensity score-weighted study of US Veterans Affairs data, maintenance pemetrexed plus pembrolizumab was not associated with improved overall survival compared with maintenance pembrolizumab alone. The combination was, however, associated with higher risks of acute kidney injury, neutropenia, and anemia. The findings, published in JCO Oncology Practice, suggest that the incremental value of maintenance pemetrexed deserves prospective reassessment in the immunotherapy era.”
Retevmo lowers recurrence risk in early-stage RET-positive lung cancer
“Key Takeaways: LIBRETTO-432 randomized 151 adults with stage 1B–3A RET fusion–positive NSCLC post-surgery/radiotherapy ± systemic therapy to selpercatinib versus placebo for up to three years. In stage 2–3A, 2-year EFS was 92% versus 61%, corresponding to an 83% reduction in recurrence/progression/death and fewer recurrences (4 vs 19).”
Do Clinical Trial Results Hold Up in the Real World? A New Study on ALK+ Lung Cancer Says Yes—Mostly
“Key Takeaways: Claims-based comparative effectiveness showed alectinib outperformed crizotinib in overall survival and treatment persistence, supporting second-generation ALK inhibition as preferred first-line therapy in routine practice. Real-world outcome patterns closely mirrored ALEX, strengthening confidence that randomized trial benefits translate to older, sicker, and multi-morbid patients often excluded by performance status or organ dysfunction criteria.”
Active surveillance may significantly improve survival among patients with lung cancer
“Key takeaways: Medical oncologists ordered concordant chest CT scans more than other specialties. Guideline-recommended chest CT surveillance after definitive treatment was associated with improved NSCLC survival.”
New NIH Funding to Advance Lung Cancer Screening Technology
“Biomedical engineers at UConn have been awarded a R33 grant from the National Institutes of Health (NIH) to develop a breakthrough diagnostic smartphone-based platform to make early lung cancer detection faster, more affordable, accessible and less invasive.”
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer
“Conclusions and Relevance: Ivonescimab plus chemotherapy provided a statistically significant and clinically meaningful improvement in overall survival with an acceptable safety profile in patients with EGFR-variant NSCLC after EGFR-TKI therapy.”
Targeted Therapy Improves Survival in EGFR-Mutated Lung Cancer After TKI Failure
“Survival outcomes were significantly better with sacituzumab tirumotecan monotherapy than with standard pemetrexed plus platinum-based chemotherapy in patients with EGFR-mutated advanced non–small-cell lung cancer (NSCLC) that progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Researchers reported the findings in The New England Journal of Medicine.”
Phase 3 LAGOON Trial Fails to Confirm Survival Benefit of Lurbinectedin in Relapsed SCLC
“Key Takeaways: A 724-patient, 3-arm randomization showed median OS of 8.7 months (lurbinectedin), 10.9 months (lurbinectedin–irinotecan), and 10.7 months (control), without statistically significant hazard ratios. Broader eligibility versus the phase 2 dataset included prior CNS metastases, potentially diluting benefit signals and complicating cross-trial comparisons supporting accelerated approval.”
KRAS Q61-Mutant NSCLC Shows Distinct Molecular Patterns and Better Outcomes With Immunotherapy-Based Regimens
“The findings suggest that KRAS Q61-mutant NSCLC is not a single uniform disease group. The two dominant subtypes, KRAS Q61H and KRAS Q61L, showed distinct clinical and co-mutational profiles. Importantly, immunotherapy-based first-line treatment was associated with more favorable outcomes than chemotherapy alone.”
Jazz Pharmaceuticals lung cancer drug fails main trial goal
“June 12 (Reuters) – Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca failed to meet the main goal of improving overall survival in a late-stage study, potentially risking its current regulatory status.”
